Who Paid My Doc
A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra
Research payments
$4,273,743
Through program year 2024, $4,273,743 in research payments was reported against A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra, across 1,885 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,000 | 2 |
| 2023 | Research | $318,055 | 135 |
| 2022 | Research | $3,412,749 | 1,600 |
| 2021 | Research | $449,010 | 132 |
| 2020 | Research | $92,929 | 16 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Peter Silas Layton, UT Named on 109 payments
- Mary Tipton South Jordan, UT Named on 76 payments
- William Byars Greenville, SC Named on 75 payments
- Jake Jones Salt Lake Cty, UT Named on 68 payments
- Keith Pulvermacher Marshfield, WI Named on 49 payments
- John Scott Richmond, VA Named on 49 payments
- Richard Aguilar Nampa, ID Named on 48 payments
- Kevin Rouse Jonesboro, AR Named on 43 payments
- Ryan Gottfredson Orem, UT Named on 43 payments
- Anu George Falls Church, VA Named on 38 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.